Need professional-grade analysis? Visit stockanalysis.com
$35.90M
N/A
N/A
N/A
Passage Bio Inc (PASG) trades on United States in USD. The company is classified in the Healthcare sector under the Biological Products industry. The stock currently trades at $5.90, down 3.75% from the previous close.
Over the past year, PASG has traded between a low of $5.27 and a high of $19.85. The stock has lost 9.2% over this period. It is currently 70.3% below its 52-week high.
Passage Bio Inc has a market capitalization of $35.90M.
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other programs for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is based in Philadelphia, Pennsylvania.
Side-by-side comparison against top Healthcare peers.